Skip to content
Home/Companies/Biotech/Synthace
SY

Synthace

Biotech·UK·Active·7yr hold

Synthace is a industry / biotech company, headquartered in United Kingdom.

Entry
2019
Hold
7yr
Status
Active
Est. EV
–

Who owns Synthace?

Synthace is currently owned by Sofinnova Partners through Sofinnova Crossover Fund I (2018 vintage), since 2019.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC

Key facts

HQUnited Kingdom
SectorIndustry / Biotech

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

GenSight Biologics
Active
BiotechFrance
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUnited Kingdom· 2021
to
Artios Pharma
Active
BiotechUK· 2020
Calliditas
Exited 2024
BiotechSweden· 2020
to
Hemab Therapeutics
Active
BiotechDenmark· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings